Article info
PDFRegular and Young Investigator Award Abstracts
Combination Immunotherapies
794 TKM-011, Anti-CD20 antibody confers multi-properties against burkitt’s lymphoma in comparable efficacy to rituximab and obinutuzumab
Citation
794 TKM-011, Anti-CD20 antibody confers multi-properties against burkitt’s lymphoma in comparable efficacy to rituximab and obinutuzumab
Publication history
- First published November 7, 2022.
Online issue publication
April 26, 2023
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.